Much of the excitement among professional investors is around a second drug – NNZ-2591 – which Neuren has in a phase-two trial to treat other neurological disorders.“This product has similarities to trofinetide,” said Mr Pilcher. “The molecule has several benefits over trofinetide including better dosing and lower [cost of goods sold] to manufacture.”Neuren will report more clinical trial results for NNZ-259 in December, with Acadia already on board as a potential licence and distribution partner on similar terms to trofinetide.Nasdaq-listed shares in Acadia pointed 22.8 per cent higher on Wall Street’s after-hours market on Friday.
NEU Price at posting:
$13.47 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)